Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008134 | 0.91 | FFAR1 (0.43) | CETPMRGPRX4MCHR1KMT2AFFAR1 | |
| SCHEMBL4010505 | 0.86 | HRH3 (0.49) | MRGPRX4MCHR1 | |
| SCHEMBL4011816 | 0.85 | PPARD (0.46) | MRGPRX4MCHR1 | |
| SCHEMBL4015066 | 0.85 | KDR (0.45) | MRGPRX4MCHR1 | |
| SCHEMBL4008041 | 0.83 | NPC1 (0.53) | CETPMRGPRX4KMT2AACHE | |
| SCHEMBL4014337 | 0.82 | MCHR1 (0.43) | MRGPRX4MCHR1 | |
| SCHEMBL4014286 | 0.80 | MRGPRX4 (0.42) | CETPMRGPRX4MCHR1KMT2A | |
| SCHEMBL13683747 | 0.80 | AVPR2 (0.54) | CETPMRGPRX4MCHR1MAPK1KMT2A | |
| SCHEMBL3858066 | 0.75 | ACACB (0.46) | CETPMRGPRX4MCHR1MAPK1KMT2A | |
| SCHEMBL14209944 | 0.75 | MAPT (0.49) | CETPMCHR1MAPK1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | CETP 1290/4885MRGPRX4 45/4885MCHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.